O uso de corticoides para o tratamento da covid-19
Carregando...
Data
2021-12
Tipo de documento
Artigo Científico
Título da Revista
ISSN da Revista
Título de Volume
Área do conhecimento
Ciências da Saúde
Modalidade de acesso
Acesso aberto
Editora
Autores
Ivo, Caio Henrique de Carvalho
Orientador
Faria, Raimundo Nonato
Coorientador
Resumo
Em 2019, na cidade de Wuhan, China, surgem os primeiros casos da
doença do coronavírus 2 (COVID-19), causada pelo vírus da síndrome respiratória
aguda grave coronavírus 2 (SARS-CoV-2). A COVID-19 é uma doença transmitida por
contato direto e provoca febre, falta de ar intensa e tosse seca. Pacientes em estado
crítico da doença tendem a ter uma hiperinflamação, bem como, uma produção
exacerbada de citocinas pró-inflamatórias, esse evento favorece para a síndrome do
desconforto respiratório agudo grave (SDRA), conduzindo o paciente a uma
pneumonia e insuficiência respiratória grave, sendo estes, os principais quadros de
mortalidade associadas a doença. O presente estudo buscou avaliar os estudos
publicados sobre a utilização de corticoides no tratamento da condição inflamatória
provocada pelo SARS-COV-2. Foram encontrados um total de 806 artigos, vieram ser
retirados 708 artigos que não contemplaram os descritores propostos, estudos de
revisão e o quais não contribuiriam para o tema, assim conduziram-se apenas 98
artigos. No decorrer da seleção retiraram-se 86 artigos, referente a textos incompletos,
dados inconclusivos, artigos duplicados. Após aplicar os critérios de inclusão, foram
selecionados 12 artigos. Dos artigos selecionados foi possível coletar dados
suficientes para estabelecer regimes de tratamentos com corticosteroides. Estudos
mostraram os efeitos benéficos da metilprednisolona em pacientes com pneumonia
relacionada a COVID-19. Outros estudos também comprovaram o efeito do
tratamento precoce com corticosteroides. Portanto, pode-se concluir, que a
administração de corticosteroides pode reprimir a tempestade de citocinas presente
em pacientes graves da COVID-19, sendo capaz reduzir significativamente o risco de
morte em tais pacientes, minimizar o tempo de internação, reduzir a admissão a UTI
e ventilação mecânica.
In 2019, in the city of Wuhan, China, the first cases of coronavirus 2 disease (COVID-19) appear, caused by the severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2). COVID-19 is a disease transmitted by direct contact and causes fever, severe shortness of breath and dry cough. Patients in critical condition of the disease tend to have hyperinflammation, as well as an exacerbated production of pro-inflammatory cytokines, this event favors severe acute respiratory distress syndrome (ARDS), leading the patient to pneumonia and severe respiratory failure, these being the main mortality tables associated with the disease. The present study sought to evaluate published studies on the use of corticosteroids in the treatment of the inflammatory condition caused by SARS-COV-2. A total of 806 articles were found, 708 articles were removed that did not include the proposed descriptors, review studies and which would not contribute to the theme, so only 98 articles were conducted. During the selection, 86 articles were removed, referring to incomplete texts, inconclusive data, duplicate articles. After applying the inclusion criteria, 12 articles were selected. From the selected articles, it was possible to collect enough data to establish corticosteroid treatment regimens. Studies have shown the beneficial effects of methylprednisolone in patients with COVID-19-related pneumonia. Other studies have also proven the effect of early treatment with corticosteroids. Therefore, it can be concluded that the administration of corticosteroids can repress the cytokine storm present in critically ill patients of COVID-19, being able to significantly reduce the risk of death in such patients, minimize the length of stay, reduce admission to the ICU and mechanical ventilation.
In 2019, in the city of Wuhan, China, the first cases of coronavirus 2 disease (COVID-19) appear, caused by the severe acute respiratory syndrome virus coronavirus 2 (SARS-CoV-2). COVID-19 is a disease transmitted by direct contact and causes fever, severe shortness of breath and dry cough. Patients in critical condition of the disease tend to have hyperinflammation, as well as an exacerbated production of pro-inflammatory cytokines, this event favors severe acute respiratory distress syndrome (ARDS), leading the patient to pneumonia and severe respiratory failure, these being the main mortality tables associated with the disease. The present study sought to evaluate published studies on the use of corticosteroids in the treatment of the inflammatory condition caused by SARS-COV-2. A total of 806 articles were found, 708 articles were removed that did not include the proposed descriptors, review studies and which would not contribute to the theme, so only 98 articles were conducted. During the selection, 86 articles were removed, referring to incomplete texts, inconclusive data, duplicate articles. After applying the inclusion criteria, 12 articles were selected. From the selected articles, it was possible to collect enough data to establish corticosteroid treatment regimens. Studies have shown the beneficial effects of methylprednisolone in patients with COVID-19-related pneumonia. Other studies have also proven the effect of early treatment with corticosteroids. Therefore, it can be concluded that the administration of corticosteroids can repress the cytokine storm present in critically ill patients of COVID-19, being able to significantly reduce the risk of death in such patients, minimize the length of stay, reduce admission to the ICU and mechanical ventilation.
Palavras-chave
Covid-19 e corticoides, SARS-COV 2 e corticosteroides, Citocinas e covid19